<p>Lung adenocarcinoma (LUAD), the most prevalent subtype of non-small cell lung cancer, is characterized by strong metastatic potential and poor survival rates. Here, we identified CYP4B1 as a potential biomarker associated with LUAD progression. Through immunohistochemical analyses, we observed that CYP4B1 expression levels were significantly downregulated in tumors. Clinically, low CYP4B1 expression was correlated with shorter disease-free survival in LUAD patients, but not in those with lung squamous cell carcinoma. Functional experiments, including transwell and soft agar assays, demonstrated that CYP4B1 overexpression suppressed the migration and invasion capabilities of LUAD cells without influencing their proliferation, acting through Sp1-mediated Slug downregulation. These findings establish the CYP4B1/Slug axis as a LUAD-associated regulatory mechanism and highlight its potential as a therapeutic target, underscoring the importance of molecular stratification in precision oncology.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

CYP4B1 inhibits lung adenocarcinoma metastasis by downregulating slug transcription via Sp1

  • Sijia Wang,
  • Yijie Liu,
  • Yuan Yu,
  • Shuwei Ren,
  • Weiwei Lin,
  • Kemeng Qiang,
  • Haishan Huang,
  • Honglei Jin

摘要

Lung adenocarcinoma (LUAD), the most prevalent subtype of non-small cell lung cancer, is characterized by strong metastatic potential and poor survival rates. Here, we identified CYP4B1 as a potential biomarker associated with LUAD progression. Through immunohistochemical analyses, we observed that CYP4B1 expression levels were significantly downregulated in tumors. Clinically, low CYP4B1 expression was correlated with shorter disease-free survival in LUAD patients, but not in those with lung squamous cell carcinoma. Functional experiments, including transwell and soft agar assays, demonstrated that CYP4B1 overexpression suppressed the migration and invasion capabilities of LUAD cells without influencing their proliferation, acting through Sp1-mediated Slug downregulation. These findings establish the CYP4B1/Slug axis as a LUAD-associated regulatory mechanism and highlight its potential as a therapeutic target, underscoring the importance of molecular stratification in precision oncology.